Vernalis Restructures, Gives Up U.S. Frova Rights To Increase Cash Reserves
This article was originally published in The Pink Sheet Daily
Executive Summary
UK company's decision to lay off almost half its workforce, divest Parkinson's therapy Apokyn and shut down U.S. operations stems from "not approvable" letter for Frova last fall for menstrual migraine.